The Journal of Heart and Lung Transplantation
Volume 29, Issue 8 , Pages 841-846 , August 2010

Prostacyclin administration errors in pulmonary arterial hypertension patients admitted to hospitals in the United States: a national survey

  • Martha S. Kingman, MS

      Affiliations

    • Department of Internal Medicine, Division of Pulmonary, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas
    • Corresponding Author InformationReprint requests: Martha S. Kingman, MS, Pulmonary Hypertension Program Heart and Lung Center, 5939 Harry Hines Blvd., Suite 600 Dallas, TX 75390. Telephone: 214 645-5529. Fax: 214 645-5536
    • ,
  • Mark A. Tankersley, PhD

      Affiliations

    • Accredo Health, Memphis, Tennessee
    • ,
  • Sandra Lombardi, RN

      Affiliations

    • Department of Pulmonary Vascular Disease, University of California at San Diego, San Diego, California
    • ,
  • Susan Spence, MS

      Affiliations

    • Heart & Vascular Center, Pulmonary Hypertension/Congestive Heart Failure Service, University of California at San Francisco, San Francisco, California
    • ,
  • Fernando Torres, MD

      Affiliations

    • Department of Internal Medicine, Division of Pulmonary, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas
    • ,
  • Kelly S. Chin, MD

      Affiliations

    • Department of Internal Medicine, Division of Pulmonary, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas
    • ,
  • Prostacyclin Safety Group

References 

  1. Badesch DB, Abman SH, Simmonneau G, et al. Medical therapy for pulmonary arterial hypertension. Chest. 2007;131:1917–1928
  2. Rubin LJ, Mendoza J, Hood M, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol) (Results of a randomized trial). Ann Intern Med. 1990;112:485–491
  3. Cuiper LL, Price PV, Christman BW. Systemic and pulmonary hypertension after abrupt cessation of prostacyclin: role of thromboxane A2. J Appl Physiol. 1996;80:191–197
  4. Finley R. http://SurveyMonkey.com(accessed November 20, 2008).
  5. Joint Commission on the Accreditation of Healthcare Organizations (JCAHO). Drug name mix-ups. FDA Patient Safety News. 2005;
  6. Institute of Medicine's (IOM) executive summary of to err is human. 2000;
  7. Roncesvalles A, Lee FW, Camamo J. Patient safety challenges in treprostinil therapy. MedSurg Nursing. 2008;17:101–106

PII: S1053-2498(10)00200-7

doi: 10.1016/j.healun.2010.03.008

The Journal of Heart and Lung Transplantation
Volume 29, Issue 8 , Pages 841-846 , August 2010

Article Tools

* Image Usage & Resolution